Help End Marijuana Prohibition (HEMP) Party

Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore

Retrieved on: 
Thursday, July 21, 2022

Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.

Key Points: 
  • Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.
  • The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
  • We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China.
  • NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.

Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment

Retrieved on: 
Thursday, June 23, 2022

Based on the data now published in peer-reviewed journals, we are encouraged about the potential of NRD.E1 to address the high unmet medical need for a non-opioid agent to treat chronic pain.

Key Points: 
  • Based on the data now published in peer-reviewed journals, we are encouraged about the potential of NRD.E1 to address the high unmet medical need for a non-opioid agent to treat chronic pain.
  • In three Phase 1 studies NRD.E1 was well tolerated as single dose up to 1200 mg and repeated doses of 300 mg/day for five consecutive days.
  • The Phase 2a study was a randomized, double-blind, placebo-controlled, dose-finding, proof-of-concept study in 88 patients with PDPN.
  • The study investigated NRD.E1 at 10, 40, or 150 mg/day or placebo over a 3-week treatment period.